RxDoctor Payments Data

Amy McCarthy, MD

Internal Medicine · Lake Orion, MINPI 1972509404

Payments from drug & device makers

$751in general payments, 2019–2025

Across 45 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$192
  • Lilly USA, LLC$166
  • Sanofi-aventis U.S. LLC$115
  • GSK$52
  • Sanofi Pasteur Inc.$49
  • Ironshore Pharmaceuticals Inc.$38
  • plus $140 from 8 others

What the payments were for

  • Food & beverage$751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$751 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$41,127
Medicare patients
155
Services billed
624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide79$115,711
OzempicSemaglutide44$72,343
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$70,020
EliquisApixaban46$59,789
JanuviaSitagliptin Phosphate20$25,156
MounjaroTirzepatide11$20,472
FarxigaDapagliflozin Propanediol18$19,486
LinzessLinaclotide14$17,564
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$15,872
Atorvastatin Calcium336$4,799
Metoprolol Succinate275$4,786
Levothyroxine Sodium263$3,183
Olmesartan Medoxomil94$2,749
Losartan Potassium209$2,526
Rosuvastatin Calcium100$2,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$166$136,18290 claims
GSKTrelegy Ellipta, Anoro Ellipta$52$85,89292 claims
Novo NordiskOzempic$192$72,34344 claims
PfizerEliquis$15$59,78946 claims
AstraZenecaFarxiga$37$19,48618 claims
AbbVieLinzess$13$17,56414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lake Orion

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →